The troriluzole clinical development program encompassed the first industry clinical trials to generate data showing ...
Mycoplasma pneumoniae infections have risen significantly post-COVID-19, presenting with both respiratory and increasing ...
A green light would have made Vyglxia the first and only FDA-approved treatment for spinocerebellar ataxia, a life-threatening neurodegenerative disease characterized by progressive loss of voluntary ...
Biohaven was seeking approval for its drug Vyglxia in the treatment of Spinocerebellar ataxia. ・The company is in the process ...
TipRanks on MSN
Why Is Biohaven Stock (BHVN) Down 40% Today?
Biohaven stock was down 40% in pre-market trading on Wednesday, following a 6.06% fall yesterday. The stock has also ...
When it didn’t go away they brought her to the Women’s and Children’s Hospital where she was diagnosed with cerebellitis, ...
The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Biohaven regarding the New Drug Application (NDA) for troriluzole for the treatment of adults with spinocerebellar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback